Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126272121 | 12627212 | 1 | I | 2016 | 20160727 | 20160805 | 20160805 | EXP | FR-SA-2016SA139032 | AVENTIS | 81.00 | YR | E | M | Y | 0.00000 | 20160805 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126272121 | 12627212 | 1 | I | KARDEGIC | ASPIRIN LYSINE | 1 | Oral | Y | UNK | 0 | 1 | DF | ORAL POWDER | QD | |||||
| 126272121 | 12627212 | 2 | I | KARDEGIC | ASPIRIN LYSINE | 1 | Oral | Y | UNKNOWN | 0 | ORAL POWDER | ||||||||
| 126272121 | 12627212 | 3 | PS | CLOPIDOGREL BISULFATE. | CLOPIDOGREL BISULFATE | 1 | Oral | Y | UNKNOWN | 20839 | 75 | MG | QD | ||||||
| 126272121 | 12627212 | 4 | I | SEROPLEX | ESCITALOPRAM OXALATE | 1 | Oral | UNK | 0 | 10 | MG | FILM-COATED TABLET | QD | ||||||
| 126272121 | 12627212 | 5 | C | BISOPROLOL | BISOPROLOL | 1 | 0 | 1 | DF | TABLET | QD | ||||||||
| 126272121 | 12627212 | 6 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | QD | |||||||||||
| 126272121 | 12627212 | 7 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | 1 | DF | TABLET | QD | ||||||||
| 126272121 | 12627212 | 8 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | 1 | DF | TABLET | QD | ||||||||
| 126272121 | 12627212 | 9 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | 0 | QD | |||||||||||
| 126272121 | 12627212 | 10 | C | XATRAL LP | ALFUZOSIN | 1 | 0 | 1 | DF | TABLET | QD | ||||||||
| 126272121 | 12627212 | 11 | C | DOLIPRANE | ACETAMINOPHEN | 1 | 0 | ||||||||||||
| 126272121 | 12627212 | 12 | C | METHOTREXATE. | METHOTREXATE | 1 | 0 | 40 | MG | /wk |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126272121 | 12627212 | 1 | Vascular device user |
| 126272121 | 12627212 | 2 | Vascular device user |
| 126272121 | 12627212 | 3 | Vascular device user |
| 126272121 | 12627212 | 4 | Depressive symptom |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126272121 | 12627212 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126272121 | 12627212 | Anaemia | |
| 126272121 | 12627212 | Epistaxis | |
| 126272121 | 12627212 | Melaena |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126272121 | 12627212 | 1 | 20160505 | 0 | ||
| 126272121 | 12627212 | 3 | 20160505 | 0 | ||
| 126272121 | 12627212 | 7 | 20160505 | 0 |